Survodutide

Survodutide (BI 456906) is a dual-acting peptide that activates both GLP-1 and glucagon receptors, designed to leverage the complementary metabolic effects of both hormones for weight management and metabolic liver disease. Unlike triple agonists that add GIP activity, survodutide focuses on the GLP-1/glucagon combination.

The glucagon receptor activation provides unique metabolic benefits including enhanced hepatic fatty acid oxidation, increased energy expenditure through thermogenesis, and direct effects on liver metabolism. These complement GLP-1's appetite-suppressing and insulin-sensitizing effects to produce comprehensive metabolic improvement.

Clinical research has focused particularly on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), where survodutide's combined effects on hepatic fat metabolism, body weight, and metabolic parameters address multiple aspects of the disease. Phase 2 data show substantial liver fat reduction and histological improvement.

The compound represents an alternative approach to metabolic peptide design compared to the GIP-inclusive dual and triple agonists, hypothesizing that glucagon's hepatic and thermogenic effects may be more beneficial than GIP for certain metabolic conditions, particularly those involving liver pathology.